Supplemental methods, Tables S1, S2, S3,S4, S5, Figures S1, S2, S3, S4. from Inhibition of Notch Signaling Enhances Chemosensitivity in B-cell Precursor Acute Lymphoblastic Leukemia

Résumé fourni par la source

Supplemental Methods describes methods that were not thoroughly described in the main manuscript as well as methods used to produce supplemental data. Table S1 describes characteristics of patients involved in the study. Table S2 describes genes potentially damages in 5 B-ALL patients following DNA sequencing. Table S3 describes, epigenetics patterns of ALL patients as obtained following the processing of methylation data publicly available under accession number GSE49031. Table S4 describes Chi Square analysis of the association between Notch expression level and response to therapy. Table S5 describes B-ALL cell survival upon treatment with Notch ligands. Figure S1 describes expression of Notch target genes and Notch active forms in B-ALL samples. This figure also displays the validation of L5C5 antibody in HEK 293T cells. Figures S2 describes the sensitivity (Annexin V) of B-ALL samples to Ara-C, Doxorubicin and Dexamethasone, each used alone or in combination with anti-Notch3 or anti-Notch4. Figure S3 describes the sensitivity (Annexin V) of B-ALL samples to Ara-C, Doxorubicin and Dexamethasone, each used alone or in combination with different Notch inhibitors. The aim is to screen the most active (in term of cell death) association in vitro, that will then be used in vivo. Figures S4 presents how anti-oxidants NAC and BME protect B-ALL cells from cell death induced by drug treatments.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.